nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CYP1A1—Cholecalciferol—osteoporosis	0.0395	0.0892	CbGbCtD
Bortezomib—CYP1A2—Estropipate—osteoporosis	0.0343	0.0774	CbGbCtD
Bortezomib—CYP1A1—Estradiol—osteoporosis	0.0319	0.0719	CbGbCtD
Bortezomib—CYP2C9—Estropipate—osteoporosis	0.0309	0.0697	CbGbCtD
Bortezomib—CYP2C8—Raloxifene—osteoporosis	0.0296	0.0667	CbGbCtD
Bortezomib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0285	0.0644	CbGbCtD
Bortezomib—CYP2C8—Cholecalciferol—osteoporosis	0.0228	0.0515	CbGbCtD
Bortezomib—CYP2C19—Cholecalciferol—osteoporosis	0.0191	0.0432	CbGbCtD
Bortezomib—CYP2C8—Estradiol—osteoporosis	0.0184	0.0415	CbGbCtD
Bortezomib—CYP3A4—Estropipate—osteoporosis	0.018	0.0405	CbGbCtD
Bortezomib—CYP3A4—Calcitriol—osteoporosis	0.018	0.0405	CbGbCtD
Bortezomib—CYP1A2—Conjugated Estrogens—osteoporosis	0.0162	0.0366	CbGbCtD
Bortezomib—CYP2C9—Cholecalciferol—osteoporosis	0.0159	0.0359	CbGbCtD
Bortezomib—CYP2C19—Estradiol—osteoporosis	0.0154	0.0348	CbGbCtD
Bortezomib—CYP2D6—Cholecalciferol—osteoporosis	0.0146	0.0328	CbGbCtD
Bortezomib—CYP3A4—Ergocalciferol—osteoporosis	0.0144	0.0324	CbGbCtD
Bortezomib—CYP1A2—Estradiol—osteoporosis	0.0142	0.0321	CbGbCtD
Bortezomib—CYP2C9—Estradiol—osteoporosis	0.0128	0.0289	CbGbCtD
Bortezomib—CYP3A4—Raloxifene—osteoporosis	0.012	0.027	CbGbCtD
Bortezomib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0116	0.0261	CbGbCtD
Bortezomib—CYP3A4—Cholecalciferol—osteoporosis	0.00926	0.0209	CbGbCtD
Bortezomib—CYP3A4—Conjugated Estrogens—osteoporosis	0.0085	0.0192	CbGbCtD
Bortezomib—CYP3A4—Estradiol—osteoporosis	0.00746	0.0168	CbGbCtD
Bortezomib—PSMA1—uterus—osteoporosis	0.00218	0.0971	CbGeAlD
Bortezomib—CTSG—bone marrow—osteoporosis	0.00193	0.0859	CbGeAlD
Bortezomib—PSMA1—bone marrow—osteoporosis	0.00185	0.0824	CbGeAlD
Bortezomib—PSMD1—uterus—osteoporosis	0.00183	0.0816	CbGeAlD
Bortezomib—PSMD2—Fulvestrant—Estradiol—osteoporosis	0.00163	0.402	CbGdCrCtD
Bortezomib—PSMD2—uterus—osteoporosis	0.00162	0.0722	CbGeAlD
Bortezomib—PSMD1—bone marrow—osteoporosis	0.00155	0.0692	CbGeAlD
Bortezomib—PSMB5—uterus—osteoporosis	0.00142	0.0634	CbGeAlD
Bortezomib—PSMD2—bone marrow—osteoporosis	0.00138	0.0613	CbGeAlD
Bortezomib—PSMB8—bone marrow—osteoporosis	0.00137	0.0609	CbGeAlD
Bortezomib—Lacosamide—CA2—osteoporosis	0.00127	1	CrCbGaD
Bortezomib—PSMB1—uterus—osteoporosis	0.00124	0.0554	CbGeAlD
Bortezomib—PSMB2—uterus—osteoporosis	0.00121	0.0541	CbGeAlD
Bortezomib—PSMB5—bone marrow—osteoporosis	0.00121	0.0538	CbGeAlD
Bortezomib—PSMB1—bone marrow—osteoporosis	0.00106	0.0471	CbGeAlD
Bortezomib—PSMB2—bone marrow—osteoporosis	0.00103	0.0459	CbGeAlD
Bortezomib—SLC31A1—bone marrow—osteoporosis	0.000892	0.0398	CbGeAlD
Bortezomib—PSMB8—Estradiol valerate/Dienogest—Estradiol—osteoporosis	0.000885	0.219	CbGdCrCtD
Bortezomib—PSMB8—Estradiol valerate/Dienogest—Ethinyl Estradiol—osteoporosis	0.000864	0.214	CbGdCrCtD
Bortezomib—PSMB8—Norethindrone—Ethinyl Estradiol—osteoporosis	0.000371	0.0918	CbGdCrCtD
Bortezomib—CYP1A1—uterus—osteoporosis	0.000357	0.0159	CbGeAlD
Bortezomib—PTGS1—uterus—osteoporosis	0.000314	0.014	CbGeAlD
Bortezomib—PSMB8—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000295	0.0731	CbGdCrCtD
Bortezomib—Hypersensitivity—Ibandronate—osteoporosis	8.16e-05	0.000303	CcSEcCtD
Bortezomib—Cough—Conjugated Estrogens—osteoporosis	8.16e-05	0.000303	CcSEcCtD
Bortezomib—Dyspnoea—Risedronate—osteoporosis	8.14e-05	0.000302	CcSEcCtD
Bortezomib—Erythema multiforme—Estradiol—osteoporosis	8.13e-05	0.000301	CcSEcCtD
Bortezomib—Hypotension—Pamidronate—osteoporosis	8.11e-05	0.000301	CcSEcCtD
Bortezomib—Convulsion—Conjugated Estrogens—osteoporosis	8.11e-05	0.0003	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	8.09e-05	0.0003	CcSEcCtD
Bortezomib—Fatigue—Ethinyl Estradiol—osteoporosis	8.07e-05	0.000299	CcSEcCtD
Bortezomib—Pruritus—Alendronate—osteoporosis	8.05e-05	0.000298	CcSEcCtD
Bortezomib—Dyspepsia—Risedronate—osteoporosis	8.04e-05	0.000298	CcSEcCtD
Bortezomib—Eye disorder—Estradiol—osteoporosis	8.04e-05	0.000298	CcSEcCtD
Bortezomib—Tinnitus—Estradiol—osteoporosis	8.02e-05	0.000297	CcSEcCtD
Bortezomib—Constipation—Ethinyl Estradiol—osteoporosis	8.01e-05	0.000297	CcSEcCtD
Bortezomib—Confusional state—Zoledronate—osteoporosis	7.99e-05	0.000296	CcSEcCtD
Bortezomib—Hypersensitivity—Calcitriol—osteoporosis	7.99e-05	0.000296	CcSEcCtD
Bortezomib—Cardiac disorder—Estradiol—osteoporosis	7.98e-05	0.000296	CcSEcCtD
Bortezomib—Flushing—Estradiol—osteoporosis	7.98e-05	0.000296	CcSEcCtD
Bortezomib—Chest pain—Conjugated Estrogens—osteoporosis	7.96e-05	0.000295	CcSEcCtD
Bortezomib—Arthralgia—Conjugated Estrogens—osteoporosis	7.96e-05	0.000295	CcSEcCtD
Bortezomib—Myalgia—Conjugated Estrogens—osteoporosis	7.96e-05	0.000295	CcSEcCtD
Bortezomib—Asthenia—Ibandronate—osteoporosis	7.95e-05	0.000295	CcSEcCtD
Bortezomib—Anxiety—Conjugated Estrogens—osteoporosis	7.94e-05	0.000294	CcSEcCtD
Bortezomib—Nausea—Etidronic acid—osteoporosis	7.93e-05	0.000294	CcSEcCtD
Bortezomib—Anaphylactic shock—Zoledronate—osteoporosis	7.93e-05	0.000294	CcSEcCtD
Bortezomib—Oedema—Zoledronate—osteoporosis	7.93e-05	0.000294	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	7.91e-05	0.000293	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Pamidronate—osteoporosis	7.91e-05	0.000293	CcSEcCtD
Bortezomib—Diarrhoea—Estropipate—osteoporosis	7.91e-05	0.000293	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Risedronate—osteoporosis	7.88e-05	0.000292	CcSEcCtD
Bortezomib—Infection—Zoledronate—osteoporosis	7.88e-05	0.000292	CcSEcCtD
Bortezomib—Fatigue—Risedronate—osteoporosis	7.87e-05	0.000292	CcSEcCtD
Bortezomib—Insomnia—Pamidronate—osteoporosis	7.85e-05	0.000291	CcSEcCtD
Bortezomib—Pruritus—Ibandronate—osteoporosis	7.84e-05	0.000291	CcSEcCtD
Bortezomib—Pain—Risedronate—osteoporosis	7.81e-05	0.000289	CcSEcCtD
Bortezomib—Constipation—Risedronate—osteoporosis	7.81e-05	0.000289	CcSEcCtD
Bortezomib—Angiopathy—Estradiol—osteoporosis	7.8e-05	0.000289	CcSEcCtD
Bortezomib—Shock—Zoledronate—osteoporosis	7.8e-05	0.000289	CcSEcCtD
Bortezomib—Paraesthesia—Pamidronate—osteoporosis	7.79e-05	0.000289	CcSEcCtD
Bortezomib—Diarrhoea—Alendronate—osteoporosis	7.79e-05	0.000289	CcSEcCtD
Bortezomib—Asthenia—Calcitriol—osteoporosis	7.78e-05	0.000288	CcSEcCtD
Bortezomib—Nervous system disorder—Zoledronate—osteoporosis	7.78e-05	0.000288	CcSEcCtD
Bortezomib—Immune system disorder—Estradiol—osteoporosis	7.77e-05	0.000288	CcSEcCtD
Bortezomib—Thrombocytopenia—Zoledronate—osteoporosis	7.76e-05	0.000288	CcSEcCtD
Bortezomib—Mediastinal disorder—Estradiol—osteoporosis	7.75e-05	0.000287	CcSEcCtD
Bortezomib—Dyspnoea—Pamidronate—osteoporosis	7.74e-05	0.000287	CcSEcCtD
Bortezomib—Tachycardia—Zoledronate—osteoporosis	7.74e-05	0.000287	CcSEcCtD
Bortezomib—Feeling abnormal—Ethinyl Estradiol—osteoporosis	7.72e-05	0.000286	CcSEcCtD
Bortezomib—Chills—Estradiol—osteoporosis	7.72e-05	0.000286	CcSEcCtD
Bortezomib—Skin disorder—Zoledronate—osteoporosis	7.7e-05	0.000286	CcSEcCtD
Bortezomib—Pruritus—Calcitriol—osteoporosis	7.67e-05	0.000284	CcSEcCtD
Bortezomib—Hyperhidrosis—Zoledronate—osteoporosis	7.67e-05	0.000284	CcSEcCtD
Bortezomib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	7.66e-05	0.000284	CcSEcCtD
Bortezomib—Diarrhoea—Raloxifene—osteoporosis	7.66e-05	0.000284	CcSEcCtD
Bortezomib—Dyspepsia—Pamidronate—osteoporosis	7.64e-05	0.000283	CcSEcCtD
Bortezomib—Dizziness—Estropipate—osteoporosis	7.64e-05	0.000283	CcSEcCtD
Bortezomib—Anaphylactic shock—Conjugated Estrogens—osteoporosis	7.63e-05	0.000283	CcSEcCtD
Bortezomib—Oedema—Conjugated Estrogens—osteoporosis	7.63e-05	0.000283	CcSEcCtD
Bortezomib—Infection—Conjugated Estrogens—osteoporosis	7.58e-05	0.000281	CcSEcCtD
Bortezomib—Diarrhoea—Ibandronate—osteoporosis	7.58e-05	0.000281	CcSEcCtD
Bortezomib—Anorexia—Zoledronate—osteoporosis	7.56e-05	0.00028	CcSEcCtD
Bortezomib—Decreased appetite—Pamidronate—osteoporosis	7.55e-05	0.00028	CcSEcCtD
Bortezomib—Mental disorder—Estradiol—osteoporosis	7.53e-05	0.000279	CcSEcCtD
Bortezomib—Dizziness—Alendronate—osteoporosis	7.53e-05	0.000279	CcSEcCtD
Bortezomib—Shock—Conjugated Estrogens—osteoporosis	7.51e-05	0.000278	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Pamidronate—osteoporosis	7.49e-05	0.000278	CcSEcCtD
Bortezomib—Nervous system disorder—Conjugated Estrogens—osteoporosis	7.49e-05	0.000278	CcSEcCtD
Bortezomib—Malnutrition—Estradiol—osteoporosis	7.49e-05	0.000278	CcSEcCtD
Bortezomib—Erythema—Estradiol—osteoporosis	7.49e-05	0.000278	CcSEcCtD
Bortezomib—Fatigue—Pamidronate—osteoporosis	7.48e-05	0.000277	CcSEcCtD
Bortezomib—Gastrointestinal pain—Risedronate—osteoporosis	7.47e-05	0.000277	CcSEcCtD
Bortezomib—Tachycardia—Conjugated Estrogens—osteoporosis	7.45e-05	0.000276	CcSEcCtD
Bortezomib—Urticaria—Ethinyl Estradiol—osteoporosis	7.44e-05	0.000276	CcSEcCtD
Bortezomib—Pain—Pamidronate—osteoporosis	7.42e-05	0.000275	CcSEcCtD
Bortezomib—Constipation—Pamidronate—osteoporosis	7.42e-05	0.000275	CcSEcCtD
Bortezomib—Diarrhoea—Calcitriol—osteoporosis	7.42e-05	0.000275	CcSEcCtD
Bortezomib—Skin disorder—Conjugated Estrogens—osteoporosis	7.42e-05	0.000275	CcSEcCtD
Bortezomib—Hypotension—Zoledronate—osteoporosis	7.41e-05	0.000275	CcSEcCtD
Bortezomib—Abdominal pain—Ethinyl Estradiol—osteoporosis	7.4e-05	0.000274	CcSEcCtD
Bortezomib—Body temperature increased—Ethinyl Estradiol—osteoporosis	7.4e-05	0.000274	CcSEcCtD
Bortezomib—Dizziness—Raloxifene—osteoporosis	7.4e-05	0.000274	CcSEcCtD
Bortezomib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	7.38e-05	0.000274	CcSEcCtD
Bortezomib—Flatulence—Estradiol—osteoporosis	7.38e-05	0.000273	CcSEcCtD
Bortezomib—Vomiting—Estropipate—osteoporosis	7.35e-05	0.000272	CcSEcCtD
Bortezomib—Dysgeusia—Estradiol—osteoporosis	7.33e-05	0.000272	CcSEcCtD
Bortezomib—Dizziness—Ibandronate—osteoporosis	7.33e-05	0.000272	CcSEcCtD
Bortezomib—Rash—Estropipate—osteoporosis	7.29e-05	0.00027	CcSEcCtD
Bortezomib—Dermatitis—Estropipate—osteoporosis	7.28e-05	0.00027	CcSEcCtD
Bortezomib—Anorexia—Conjugated Estrogens—osteoporosis	7.28e-05	0.00027	CcSEcCtD
Bortezomib—Urticaria—Risedronate—osteoporosis	7.25e-05	0.000269	CcSEcCtD
Bortezomib—Back pain—Estradiol—osteoporosis	7.24e-05	0.000268	CcSEcCtD
Bortezomib—Headache—Estropipate—osteoporosis	7.24e-05	0.000268	CcSEcCtD
Bortezomib—Vomiting—Alendronate—osteoporosis	7.24e-05	0.000268	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Zoledronate—osteoporosis	7.22e-05	0.000268	CcSEcCtD
Bortezomib—Body temperature increased—Risedronate—osteoporosis	7.22e-05	0.000268	CcSEcCtD
Bortezomib—Abdominal pain—Risedronate—osteoporosis	7.22e-05	0.000268	CcSEcCtD
Bortezomib—Muscle spasms—Estradiol—osteoporosis	7.2e-05	0.000267	CcSEcCtD
Bortezomib—Rash—Alendronate—osteoporosis	7.18e-05	0.000266	CcSEcCtD
Bortezomib—Insomnia—Zoledronate—osteoporosis	7.17e-05	0.000266	CcSEcCtD
Bortezomib—Dermatitis—Alendronate—osteoporosis	7.17e-05	0.000266	CcSEcCtD
Bortezomib—Feeling abnormal—Pamidronate—osteoporosis	7.15e-05	0.000265	CcSEcCtD
Bortezomib—Hypotension—Conjugated Estrogens—osteoporosis	7.13e-05	0.000264	CcSEcCtD
Bortezomib—Headache—Alendronate—osteoporosis	7.13e-05	0.000264	CcSEcCtD
Bortezomib—Paraesthesia—Zoledronate—osteoporosis	7.12e-05	0.000264	CcSEcCtD
Bortezomib—Vomiting—Raloxifene—osteoporosis	7.12e-05	0.000264	CcSEcCtD
Bortezomib—Gastrointestinal pain—Pamidronate—osteoporosis	7.1e-05	0.000263	CcSEcCtD
Bortezomib—Dyspnoea—Zoledronate—osteoporosis	7.07e-05	0.000262	CcSEcCtD
Bortezomib—Rash—Raloxifene—osteoporosis	7.06e-05	0.000262	CcSEcCtD
Bortezomib—Dermatitis—Raloxifene—osteoporosis	7.05e-05	0.000261	CcSEcCtD
Bortezomib—Vomiting—Ibandronate—osteoporosis	7.04e-05	0.000261	CcSEcCtD
Bortezomib—Tremor—Estradiol—osteoporosis	7.01e-05	0.00026	CcSEcCtD
Bortezomib—Headache—Raloxifene—osteoporosis	7.01e-05	0.00026	CcSEcCtD
Bortezomib—Rash—Ibandronate—osteoporosis	6.99e-05	0.000259	CcSEcCtD
Bortezomib—Dermatitis—Ibandronate—osteoporosis	6.98e-05	0.000259	CcSEcCtD
Bortezomib—Dyspepsia—Zoledronate—osteoporosis	6.98e-05	0.000259	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	6.96e-05	0.000258	CcSEcCtD
Bortezomib—Ill-defined disorder—Estradiol—osteoporosis	6.95e-05	0.000258	CcSEcCtD
Bortezomib—Headache—Ibandronate—osteoporosis	6.94e-05	0.000257	CcSEcCtD
Bortezomib—Insomnia—Conjugated Estrogens—osteoporosis	6.91e-05	0.000256	CcSEcCtD
Bortezomib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	6.9e-05	0.000256	CcSEcCtD
Bortezomib—Vomiting—Calcitriol—osteoporosis	6.9e-05	0.000256	CcSEcCtD
Bortezomib—Decreased appetite—Zoledronate—osteoporosis	6.89e-05	0.000256	CcSEcCtD
Bortezomib—Agitation—Estradiol—osteoporosis	6.88e-05	0.000255	CcSEcCtD
Bortezomib—Nausea—Estropipate—osteoporosis	6.86e-05	0.000254	CcSEcCtD
Bortezomib—Abdominal pain—Pamidronate—osteoporosis	6.86e-05	0.000254	CcSEcCtD
Bortezomib—Body temperature increased—Pamidronate—osteoporosis	6.86e-05	0.000254	CcSEcCtD
Bortezomib—Paraesthesia—Conjugated Estrogens—osteoporosis	6.86e-05	0.000254	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Zoledronate—osteoporosis	6.85e-05	0.000254	CcSEcCtD
Bortezomib—Angioedema—Estradiol—osteoporosis	6.84e-05	0.000254	CcSEcCtD
Bortezomib—Rash—Calcitriol—osteoporosis	6.84e-05	0.000254	CcSEcCtD
Bortezomib—Fatigue—Zoledronate—osteoporosis	6.84e-05	0.000253	CcSEcCtD
Bortezomib—Dermatitis—Calcitriol—osteoporosis	6.83e-05	0.000253	CcSEcCtD
Bortezomib—Dyspnoea—Conjugated Estrogens—osteoporosis	6.81e-05	0.000252	CcSEcCtD
Bortezomib—Headache—Calcitriol—osteoporosis	6.79e-05	0.000252	CcSEcCtD
Bortezomib—Pain—Zoledronate—osteoporosis	6.78e-05	0.000251	CcSEcCtD
Bortezomib—Constipation—Zoledronate—osteoporosis	6.78e-05	0.000251	CcSEcCtD
Bortezomib—Nausea—Alendronate—osteoporosis	6.76e-05	0.000251	CcSEcCtD
Bortezomib—Malaise—Estradiol—osteoporosis	6.75e-05	0.00025	CcSEcCtD
Bortezomib—Hypersensitivity—Risedronate—osteoporosis	6.73e-05	0.000249	CcSEcCtD
Bortezomib—Vertigo—Estradiol—osteoporosis	6.73e-05	0.000249	CcSEcCtD
Bortezomib—Dyspepsia—Conjugated Estrogens—osteoporosis	6.72e-05	0.000249	CcSEcCtD
Bortezomib—Asthenia—Ethinyl Estradiol—osteoporosis	6.72e-05	0.000249	CcSEcCtD
Bortezomib—Syncope—Estradiol—osteoporosis	6.71e-05	0.000249	CcSEcCtD
Bortezomib—Nausea—Raloxifene—osteoporosis	6.65e-05	0.000246	CcSEcCtD
Bortezomib—Decreased appetite—Conjugated Estrogens—osteoporosis	6.64e-05	0.000246	CcSEcCtD
Bortezomib—Pruritus—Ethinyl Estradiol—osteoporosis	6.63e-05	0.000246	CcSEcCtD
Bortezomib—Palpitations—Estradiol—osteoporosis	6.62e-05	0.000245	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	6.59e-05	0.000244	CcSEcCtD
Bortezomib—Fatigue—Conjugated Estrogens—osteoporosis	6.58e-05	0.000244	CcSEcCtD
Bortezomib—Nausea—Ibandronate—osteoporosis	6.58e-05	0.000244	CcSEcCtD
Bortezomib—Loss of consciousness—Estradiol—osteoporosis	6.58e-05	0.000244	CcSEcCtD
Bortezomib—Asthenia—Risedronate—osteoporosis	6.55e-05	0.000243	CcSEcCtD
Bortezomib—Feeling abnormal—Zoledronate—osteoporosis	6.53e-05	0.000242	CcSEcCtD
Bortezomib—Cough—Estradiol—osteoporosis	6.53e-05	0.000242	CcSEcCtD
Bortezomib—Constipation—Conjugated Estrogens—osteoporosis	6.53e-05	0.000242	CcSEcCtD
Bortezomib—Pain—Conjugated Estrogens—osteoporosis	6.53e-05	0.000242	CcSEcCtD
Bortezomib—Gastrointestinal pain—Zoledronate—osteoporosis	6.48e-05	0.00024	CcSEcCtD
Bortezomib—Hypertension—Estradiol—osteoporosis	6.46e-05	0.00024	CcSEcCtD
Bortezomib—Pruritus—Risedronate—osteoporosis	6.46e-05	0.000239	CcSEcCtD
Bortezomib—Nausea—Calcitriol—osteoporosis	6.44e-05	0.000239	CcSEcCtD
Bortezomib—Diarrhoea—Ethinyl Estradiol—osteoporosis	6.41e-05	0.000238	CcSEcCtD
Bortezomib—Hypersensitivity—Pamidronate—osteoporosis	6.4e-05	0.000237	CcSEcCtD
Bortezomib—Chest pain—Estradiol—osteoporosis	6.37e-05	0.000236	CcSEcCtD
Bortezomib—Myalgia—Estradiol—osteoporosis	6.37e-05	0.000236	CcSEcCtD
Bortezomib—Arthralgia—Estradiol—osteoporosis	6.37e-05	0.000236	CcSEcCtD
Bortezomib—Anxiety—Estradiol—osteoporosis	6.35e-05	0.000235	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	6.33e-05	0.000235	CcSEcCtD
Bortezomib—Urticaria—Zoledronate—osteoporosis	6.3e-05	0.000234	CcSEcCtD
Bortezomib—Discomfort—Estradiol—osteoporosis	6.3e-05	0.000233	CcSEcCtD
Bortezomib—Abdominal pain—Zoledronate—osteoporosis	6.27e-05	0.000232	CcSEcCtD
Bortezomib—Body temperature increased—Zoledronate—osteoporosis	6.27e-05	0.000232	CcSEcCtD
Bortezomib—Diarrhoea—Risedronate—osteoporosis	6.25e-05	0.000232	CcSEcCtD
Bortezomib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	6.24e-05	0.000231	CcSEcCtD
Bortezomib—Asthenia—Pamidronate—osteoporosis	6.23e-05	0.000231	CcSEcCtD
Bortezomib—Dizziness—Ethinyl Estradiol—osteoporosis	6.19e-05	0.00023	CcSEcCtD
Bortezomib—Confusional state—Estradiol—osteoporosis	6.16e-05	0.000228	CcSEcCtD
Bortezomib—Pruritus—Pamidronate—osteoporosis	6.14e-05	0.000228	CcSEcCtD
Bortezomib—Anaphylactic shock—Estradiol—osteoporosis	6.11e-05	0.000227	CcSEcCtD
Bortezomib—Oedema—Estradiol—osteoporosis	6.11e-05	0.000227	CcSEcCtD
Bortezomib—Infection—Estradiol—osteoporosis	6.07e-05	0.000225	CcSEcCtD
Bortezomib—Urticaria—Conjugated Estrogens—osteoporosis	6.07e-05	0.000225	CcSEcCtD
Bortezomib—Dizziness—Risedronate—osteoporosis	6.04e-05	0.000224	CcSEcCtD
Bortezomib—Body temperature increased—Conjugated Estrogens—osteoporosis	6.04e-05	0.000224	CcSEcCtD
Bortezomib—Abdominal pain—Conjugated Estrogens—osteoporosis	6.04e-05	0.000224	CcSEcCtD
Bortezomib—Shock—Estradiol—osteoporosis	6.01e-05	0.000223	CcSEcCtD
Bortezomib—Nervous system disorder—Estradiol—osteoporosis	5.99e-05	0.000222	CcSEcCtD
Bortezomib—Tachycardia—Estradiol—osteoporosis	5.96e-05	0.000221	CcSEcCtD
Bortezomib—Vomiting—Ethinyl Estradiol—osteoporosis	5.95e-05	0.000221	CcSEcCtD
Bortezomib—Diarrhoea—Pamidronate—osteoporosis	5.94e-05	0.00022	CcSEcCtD
Bortezomib—Skin disorder—Estradiol—osteoporosis	5.94e-05	0.00022	CcSEcCtD
Bortezomib—Hyperhidrosis—Estradiol—osteoporosis	5.91e-05	0.000219	CcSEcCtD
Bortezomib—Rash—Ethinyl Estradiol—osteoporosis	5.91e-05	0.000219	CcSEcCtD
Bortezomib—Dermatitis—Ethinyl Estradiol—osteoporosis	5.9e-05	0.000219	CcSEcCtD
Bortezomib—Headache—Ethinyl Estradiol—osteoporosis	5.87e-05	0.000218	CcSEcCtD
Bortezomib—Hypersensitivity—Zoledronate—osteoporosis	5.84e-05	0.000217	CcSEcCtD
Bortezomib—Vomiting—Risedronate—osteoporosis	5.81e-05	0.000215	CcSEcCtD
Bortezomib—Rash—Risedronate—osteoporosis	5.76e-05	0.000213	CcSEcCtD
Bortezomib—Dermatitis—Risedronate—osteoporosis	5.75e-05	0.000213	CcSEcCtD
Bortezomib—Dizziness—Pamidronate—osteoporosis	5.74e-05	0.000213	CcSEcCtD
Bortezomib—Headache—Risedronate—osteoporosis	5.72e-05	0.000212	CcSEcCtD
Bortezomib—Asthenia—Zoledronate—osteoporosis	5.69e-05	0.000211	CcSEcCtD
Bortezomib—Hypersensitivity—Conjugated Estrogens—osteoporosis	5.62e-05	0.000209	CcSEcCtD
Bortezomib—Pruritus—Zoledronate—osteoporosis	5.61e-05	0.000208	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Estradiol—osteoporosis	5.57e-05	0.000206	CcSEcCtD
Bortezomib—Nausea—Ethinyl Estradiol—osteoporosis	5.56e-05	0.000206	CcSEcCtD
Bortezomib—Insomnia—Estradiol—osteoporosis	5.53e-05	0.000205	CcSEcCtD
Bortezomib—Vomiting—Pamidronate—osteoporosis	5.52e-05	0.000205	CcSEcCtD
Bortezomib—Paraesthesia—Estradiol—osteoporosis	5.49e-05	0.000203	CcSEcCtD
Bortezomib—Asthenia—Conjugated Estrogens—osteoporosis	5.48e-05	0.000203	CcSEcCtD
Bortezomib—Rash—Pamidronate—osteoporosis	5.47e-05	0.000203	CcSEcCtD
Bortezomib—Dermatitis—Pamidronate—osteoporosis	5.47e-05	0.000203	CcSEcCtD
Bortezomib—Dyspnoea—Estradiol—osteoporosis	5.45e-05	0.000202	CcSEcCtD
Bortezomib—Headache—Pamidronate—osteoporosis	5.44e-05	0.000202	CcSEcCtD
Bortezomib—Diarrhoea—Zoledronate—osteoporosis	5.43e-05	0.000201	CcSEcCtD
Bortezomib—Nausea—Risedronate—osteoporosis	5.42e-05	0.000201	CcSEcCtD
Bortezomib—Pruritus—Conjugated Estrogens—osteoporosis	5.4e-05	0.0002	CcSEcCtD
Bortezomib—Dyspepsia—Estradiol—osteoporosis	5.38e-05	0.000199	CcSEcCtD
Bortezomib—Decreased appetite—Estradiol—osteoporosis	5.31e-05	0.000197	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Estradiol—osteoporosis	5.28e-05	0.000196	CcSEcCtD
Bortezomib—Fatigue—Estradiol—osteoporosis	5.27e-05	0.000195	CcSEcCtD
Bortezomib—Dizziness—Zoledronate—osteoporosis	5.24e-05	0.000194	CcSEcCtD
Bortezomib—Constipation—Estradiol—osteoporosis	5.23e-05	0.000194	CcSEcCtD
Bortezomib—Pain—Estradiol—osteoporosis	5.23e-05	0.000194	CcSEcCtD
Bortezomib—Diarrhoea—Conjugated Estrogens—osteoporosis	5.22e-05	0.000194	CcSEcCtD
Bortezomib—Nausea—Pamidronate—osteoporosis	5.16e-05	0.000191	CcSEcCtD
Bortezomib—Dizziness—Conjugated Estrogens—osteoporosis	5.05e-05	0.000187	CcSEcCtD
Bortezomib—Vomiting—Zoledronate—osteoporosis	5.04e-05	0.000187	CcSEcCtD
Bortezomib—Feeling abnormal—Estradiol—osteoporosis	5.04e-05	0.000187	CcSEcCtD
Bortezomib—Rash—Zoledronate—osteoporosis	5e-05	0.000185	CcSEcCtD
Bortezomib—Gastrointestinal pain—Estradiol—osteoporosis	5e-05	0.000185	CcSEcCtD
Bortezomib—Dermatitis—Zoledronate—osteoporosis	4.99e-05	0.000185	CcSEcCtD
Bortezomib—Headache—Zoledronate—osteoporosis	4.97e-05	0.000184	CcSEcCtD
Bortezomib—Vomiting—Conjugated Estrogens—osteoporosis	4.85e-05	0.00018	CcSEcCtD
Bortezomib—Urticaria—Estradiol—osteoporosis	4.85e-05	0.00018	CcSEcCtD
Bortezomib—Abdominal pain—Estradiol—osteoporosis	4.83e-05	0.000179	CcSEcCtD
Bortezomib—Body temperature increased—Estradiol—osteoporosis	4.83e-05	0.000179	CcSEcCtD
Bortezomib—Rash—Conjugated Estrogens—osteoporosis	4.81e-05	0.000178	CcSEcCtD
Bortezomib—Dermatitis—Conjugated Estrogens—osteoporosis	4.81e-05	0.000178	CcSEcCtD
Bortezomib—Headache—Conjugated Estrogens—osteoporosis	4.78e-05	0.000177	CcSEcCtD
Bortezomib—Nausea—Zoledronate—osteoporosis	4.71e-05	0.000175	CcSEcCtD
Bortezomib—Nausea—Conjugated Estrogens—osteoporosis	4.53e-05	0.000168	CcSEcCtD
Bortezomib—Hypersensitivity—Estradiol—osteoporosis	4.5e-05	0.000167	CcSEcCtD
Bortezomib—Asthenia—Estradiol—osteoporosis	4.38e-05	0.000163	CcSEcCtD
Bortezomib—Pruritus—Estradiol—osteoporosis	4.32e-05	0.00016	CcSEcCtD
Bortezomib—Diarrhoea—Estradiol—osteoporosis	4.18e-05	0.000155	CcSEcCtD
Bortezomib—Dizziness—Estradiol—osteoporosis	4.04e-05	0.00015	CcSEcCtD
Bortezomib—Vomiting—Estradiol—osteoporosis	3.89e-05	0.000144	CcSEcCtD
Bortezomib—Rash—Estradiol—osteoporosis	3.85e-05	0.000143	CcSEcCtD
Bortezomib—Dermatitis—Estradiol—osteoporosis	3.85e-05	0.000143	CcSEcCtD
Bortezomib—Headache—Estradiol—osteoporosis	3.83e-05	0.000142	CcSEcCtD
Bortezomib—Nausea—Estradiol—osteoporosis	3.63e-05	0.000135	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—IRS1—osteoporosis	7.74e-06	2.99e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CA2—osteoporosis	7.69e-06	2.97e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—OXCT1—osteoporosis	7.69e-06	2.97e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7.68e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ATIC—osteoporosis	7.66e-06	2.96e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PNP—osteoporosis	7.66e-06	2.96e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ADCY5—osteoporosis	7.65e-06	2.95e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.64e-06	2.95e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CA2—osteoporosis	7.62e-06	2.94e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—OXCT1—osteoporosis	7.62e-06	2.94e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—POMC—osteoporosis	7.53e-06	2.9e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SPP1—osteoporosis	7.5e-06	2.89e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SPP1—osteoporosis	7.5e-06	2.89e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—SPP1—osteoporosis	7.5e-06	2.89e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MGLL—osteoporosis	7.49e-06	2.89e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—POMC—osteoporosis	7.49e-06	2.89e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—POMC—osteoporosis	7.46e-06	2.88e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MGLL—osteoporosis	7.43e-06	2.87e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ENO1—osteoporosis	7.42e-06	2.86e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—SPP1—osteoporosis	7.4e-06	2.85e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6R—osteoporosis	7.34e-06	2.83e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PSMA5—osteoporosis	7.31e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PSMA2—osteoporosis	7.31e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6R—osteoporosis	7.31e-06	2.82e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP27A1—osteoporosis	7.3e-06	2.82e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6R—osteoporosis	7.27e-06	2.81e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IGF1—osteoporosis	7.24e-06	2.79e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—POMC—osteoporosis	7.23e-06	2.79e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IGF1—osteoporosis	7.2e-06	2.78e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—TPI1—osteoporosis	7.2e-06	2.78e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IGF1—osteoporosis	7.17e-06	2.77e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ACP5—osteoporosis	7.1e-06	2.74e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	7.01e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7e-06	2.7e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—IDH2—osteoporosis	6.93e-06	2.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—POMC—osteoporosis	6.82e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—POMC—osteoporosis	6.82e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—POMC—osteoporosis	6.82e-06	2.63e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PKM—osteoporosis	6.82e-06	2.63e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—FDPS—osteoporosis	6.82e-06	2.63e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IRS2—osteoporosis	6.78e-06	2.62e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IRS2—osteoporosis	6.78e-06	2.62e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IRS2—osteoporosis	6.78e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—P4HB—osteoporosis	6.77e-06	2.61e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—POMC—osteoporosis	6.73e-06	2.59e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—MYC—osteoporosis	6.69e-06	2.58e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IRS2—osteoporosis	6.69e-06	2.58e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—MYC—osteoporosis	6.66e-06	2.57e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GAPDH—osteoporosis	6.64e-06	2.56e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—LEP—osteoporosis	6.64e-06	2.56e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—LEP—osteoporosis	6.64e-06	2.56e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—LEP—osteoporosis	6.64e-06	2.56e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—MYC—osteoporosis	6.63e-06	2.56e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—TPI1—osteoporosis	6.6e-06	2.55e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1B—osteoporosis	6.55e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1B—osteoporosis	6.55e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1B—osteoporosis	6.55e-06	2.53e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—LEP—osteoporosis	6.55e-06	2.53e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—OXCT1—osteoporosis	6.51e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CA2—osteoporosis	6.51e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP27A1—osteoporosis	6.51e-06	2.51e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—RAP1A—osteoporosis	6.47e-06	2.5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PGLS—osteoporosis	6.46e-06	2.49e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPD2—osteoporosis	6.46e-06	2.49e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1B—osteoporosis	6.45e-06	2.49e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—IDH2—osteoporosis	6.37e-06	2.46e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MGLL—osteoporosis	6.35e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ESR1—osteoporosis	6.34e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ESR1—osteoporosis	6.34e-06	2.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ESR1—osteoporosis	6.34e-06	2.45e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ACP5—osteoporosis	6.34e-06	2.44e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—IDH2—osteoporosis	6.32e-06	2.44e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	6.26e-06	2.41e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ESR1—osteoporosis	6.25e-06	2.41e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—MYC—osteoporosis	6.21e-06	2.4e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—P4HB—osteoporosis	6.2e-06	2.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—osteoporosis	6.2e-06	2.39e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—MYC—osteoporosis	6.18e-06	2.39e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—osteoporosis	6.17e-06	2.38e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—MYC—osteoporosis	6.15e-06	2.37e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—osteoporosis	6.14e-06	2.37e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GAPDH—osteoporosis	6.09e-06	2.35e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP27A1—osteoporosis	5.99e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	5.99e-06	2.31e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP27A1—osteoporosis	5.94e-06	2.29e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP19A1—osteoporosis	5.93e-06	2.29e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—RAP1A—osteoporosis	5.93e-06	2.29e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IRS1—osteoporosis	5.92e-06	2.29e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IRS1—osteoporosis	5.92e-06	2.29e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IRS1—osteoporosis	5.92e-06	2.29e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ATIC—osteoporosis	5.91e-06	2.28e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PNP—osteoporosis	5.91e-06	2.28e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—TPI1—osteoporosis	5.89e-06	2.27e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IRS1—osteoporosis	5.84e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ACP5—osteoporosis	5.83e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ACP5—osteoporosis	5.78e-06	2.23e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—POMC—osteoporosis	5.7e-06	2.2e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—POMC—osteoporosis	5.7e-06	2.2e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—POMC—osteoporosis	5.7e-06	2.2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.7e-06	2.2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.64e-06	2.18e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—POMC—osteoporosis	5.62e-06	2.17e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6R—osteoporosis	5.56e-06	2.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6R—osteoporosis	5.56e-06	2.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6R—osteoporosis	5.56e-06	2.15e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—P4HB—osteoporosis	5.54e-06	2.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IGF1—osteoporosis	5.49e-06	2.12e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IGF1—osteoporosis	5.49e-06	2.12e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IGF1—osteoporosis	5.49e-06	2.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6R—osteoporosis	5.49e-06	2.12e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GAPDH—osteoporosis	5.44e-06	2.1e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—TPI1—osteoporosis	5.42e-06	2.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IGF1—osteoporosis	5.41e-06	2.09e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—IDH2—osteoporosis	5.4e-06	2.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—TPI1—osteoporosis	5.37e-06	2.07e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—RAP1A—osteoporosis	5.29e-06	2.04e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ENO1—osteoporosis	5.23e-06	2.02e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	5.17e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PSMA2—osteoporosis	5.15e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PSMA5—osteoporosis	5.15e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—P4HB—osteoporosis	5.09e-06	1.97e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP27A1—osteoporosis	5.07e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—osteoporosis	5.07e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—osteoporosis	5.07e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—osteoporosis	5.07e-06	1.96e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—osteoporosis	5.06e-06	1.95e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—P4HB—osteoporosis	5.05e-06	1.95e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—osteoporosis	5.03e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CA2—osteoporosis	5.03e-06	1.94e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—OXCT1—osteoporosis	5.03e-06	1.94e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—osteoporosis	5.01e-06	1.93e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—osteoporosis	5e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GAPDH—osteoporosis	5e-06	1.93e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GAPDH—osteoporosis	4.96e-06	1.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ACP5—osteoporosis	4.94e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MGLL—osteoporosis	4.9e-06	1.89e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.87e-06	1.88e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RAP1A—osteoporosis	4.87e-06	1.88e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ADCY5—osteoporosis	4.85e-06	1.87e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GPX1—osteoporosis	4.83e-06	1.86e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RAP1A—osteoporosis	4.83e-06	1.86e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO1—osteoporosis	4.79e-06	1.85e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PSMA5—osteoporosis	4.72e-06	1.82e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PSMA2—osteoporosis	4.72e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—osteoporosis	4.71e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—osteoporosis	4.71e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—osteoporosis	4.71e-06	1.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—osteoporosis	4.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—osteoporosis	4.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—osteoporosis	4.7e-06	1.81e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—osteoporosis	4.67e-06	1.8e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—osteoporosis	4.65e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—osteoporosis	4.64e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—osteoporosis	4.63e-06	1.79e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—osteoporosis	4.63e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.62e-06	1.78e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TPI1—osteoporosis	4.59e-06	1.77e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MTHFR—osteoporosis	4.46e-06	1.72e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—osteoporosis	4.35e-06	1.68e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—osteoporosis	4.34e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—osteoporosis	4.33e-06	1.67e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—osteoporosis	4.32e-06	1.67e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—P4HB—osteoporosis	4.31e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—osteoporosis	4.31e-06	1.66e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—osteoporosis	4.3e-06	1.66e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO1—osteoporosis	4.28e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GAPDH—osteoporosis	4.24e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PSMA2—osteoporosis	4.22e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PSMA5—osteoporosis	4.22e-06	1.63e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.21e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP19A1—osteoporosis	4.18e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—IDH2—osteoporosis	4.17e-06	1.61e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RAP1A—osteoporosis	4.13e-06	1.59e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO1—osteoporosis	3.94e-06	1.52e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.92e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO1—osteoporosis	3.9e-06	1.51e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSMA2—osteoporosis	3.88e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSMA5—osteoporosis	3.88e-06	1.5e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSMA2—osteoporosis	3.85e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSMA5—osteoporosis	3.85e-06	1.48e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—osteoporosis	3.83e-06	1.48e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—osteoporosis	3.83e-06	1.48e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—osteoporosis	3.83e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP19A1—osteoporosis	3.83e-06	1.48e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ACP5—osteoporosis	3.81e-06	1.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—osteoporosis	3.78e-06	1.46e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.6e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—POMC—osteoporosis	3.57e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TPI1—osteoporosis	3.54e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—osteoporosis	3.54e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—osteoporosis	3.54e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—osteoporosis	3.54e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—osteoporosis	3.49e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP19A1—osteoporosis	3.42e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ADCY5—osteoporosis	3.42e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GPX1—osteoporosis	3.4e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO1—osteoporosis	3.33e-06	1.29e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—P4HB—osteoporosis	3.33e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—osteoporosis	3.3e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—osteoporosis	3.3e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—osteoporosis	3.3e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—osteoporosis	3.29e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—osteoporosis	3.29e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—osteoporosis	3.29e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMA2—osteoporosis	3.29e-06	1.27e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSMA5—osteoporosis	3.29e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—osteoporosis	3.27e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GAPDH—osteoporosis	3.27e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—osteoporosis	3.25e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—osteoporosis	3.25e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—osteoporosis	3.24e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—osteoporosis	3.24e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RAP1A—osteoporosis	3.18e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP19A1—osteoporosis	3.15e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—osteoporosis	3.14e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ADCY5—osteoporosis	3.13e-06	1.21e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GPX1—osteoporosis	3.12e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP19A1—osteoporosis	3.12e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—osteoporosis	2.88e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ADCY5—osteoporosis	2.8e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GPX1—osteoporosis	2.79e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP19A1—osteoporosis	2.67e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—osteoporosis	2.57e-06	9.93e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ADCY5—osteoporosis	2.57e-06	9.92e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—osteoporosis	2.57e-06	9.92e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GPX1—osteoporosis	2.56e-06	9.89e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ADCY5—osteoporosis	2.55e-06	9.83e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GPX1—osteoporosis	2.54e-06	9.8e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMA5—osteoporosis	2.54e-06	9.78e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSMA2—osteoporosis	2.54e-06	9.78e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—osteoporosis	2.51e-06	9.69e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—osteoporosis	2.48e-06	9.56e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—osteoporosis	2.48e-06	9.56e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—osteoporosis	2.48e-06	9.56e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—osteoporosis	2.44e-06	9.43e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—osteoporosis	2.36e-06	9.12e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—osteoporosis	2.34e-06	9.04e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—osteoporosis	2.3e-06	8.89e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ADCY5—osteoporosis	2.18e-06	8.4e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GPX1—osteoporosis	2.17e-06	8.37e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.06e-06	7.94e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—osteoporosis	2.06e-06	7.93e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—osteoporosis	2e-06	7.73e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—osteoporosis	1.89e-06	7.3e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—osteoporosis	1.87e-06	7.23e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.68e-06	6.49e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GPX1—osteoporosis	1.68e-06	6.46e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—osteoporosis	1.6e-06	6.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.55e-06	5.96e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—osteoporosis	1.24e-06	4.77e-06	CbGpPWpGaD
